keyword
https://read.qxmd.com/read/38095716/pharmacotherapy-for-adhd-in-children-and-adolescents-a-summary-and-overview-of-different-european-guidelines
#21
REVIEW
L Van Vyve, B Dierckx, C G Lim, M Danckaerts, B C P Koch, A Häge, T Banaschewski
Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by a persistent pattern of inattention, hyperactivity, and impulsivity. It is the most common neurodevelopmental disorder presenting to pediatric services, and pediatricians are often involved in the early assessment, diagnosis, and treatment of children with ADHD. The treatment of ADHD typically involves a multimodal approach that encompasses a combination of psychoeducation, parent/teacher training, psychosocial/psychotherapeutic interventions, and pharmacotherapy...
March 2024: European Journal of Pediatrics
https://read.qxmd.com/read/38084067/treatment-utilization-pattern-of-preschool-children-with-attention-deficit-hyperactivity-disorder
#22
JOURNAL ARTICLE
Raman Baweja, Ritika Baweja, Hunter Weidlich, Jennifer E Nyland, Daniel A Waschbusch, James G Waxmonsky
OBJECTIVE: The aim of this study was to identify patterns of ADHD care, including factors that guide selection and sequencing of treatments in a large nationwide sample of preschool-aged youth over the past 6 years. METHOD: A retrospective cohort study utilizing a large electronic health record (TriNetX) of nearly 24,000 children ages 3 to 6 diagnosed with ADHD. RESULTS: One in three preschoolers with ADHD were prescribed psychotropic medication, most commonly methylphenidate and guanfacine...
December 12, 2023: Journal of Attention Disorders
https://read.qxmd.com/read/38064009/anxiety-and-dysautonomia-symptoms-in-patients-with-a-na-v-1-7-mutation-and-the-potential-benefits-of-low-dose-short-acting-guanfacine
#23
JOURNAL ARTICLE
Rita de Cássia Collaço, Maxime Lammens, Carley Blevins, Kristen Rodgers, Andrei Gurau, Suguru Yamauchi, Christine Kim, Jeannine Forrester, Edward Liu, Jinny Ha, Yuping Mei, Corrine Boehm, Elizabeth Wohler, Nara Sobreira, Peter C Rowe, David Valle, Malcolm V Brock, Frank Bosmans
PURPOSE: Guanfacine is an α2A -adrenergic receptor agonist, FDA-approved to treat attention-deficit hyperactivity disorder and high blood pressure, typically as an extended-release formulation up to 7 mg/day. In our dysautonomia clinic, we observed that off-label use of short-acting guanfacine at 1 mg/day facilitated symptom relief in two families with multiple members presenting with severe generalized anxiety. We also noted anecdotal improvements in associated dysautonomia symptoms such as hyperhidrosis, cognitive impairment, and palpitations...
December 8, 2023: Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society
https://read.qxmd.com/read/38059346/practical-clinical-guidelines-and-pharmacological-treatment-for-attention-deficit-hyperactivity-disorder-in-asia
#24
REVIEW
Kentaro Kawabe, Fumie Horiuchi, Yu Matsumoto, Saori Inoue, Maya Okazawa, Rie Hosokawa, Kiwamu Nakachi, Junya Soga, Shu-Ichi Ueno
Attention-deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)-approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first-line treatment, with pharmacological treatment added as the second-line treatment...
December 7, 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38045460/psychotherapeutic-drug-induced-life-threatening-arrhythmias-a-retrospective-analysis-using-the-japanese-adverse-drug-event%C3%A2-report-database
#25
JOURNAL ARTICLE
Saki Yokohara, Masayuki Hashiguchi, Tsuyoshi Shiga
BACKGROUND: Drug-induced life-threatening ventricular arrhythmias including torsade de pointes (TdP), ventricular tachycardia (VT), and ventricular fibrillation (VF) are serious cardiac side effects. Psychotherapeutic drugs are known to be risk factors for arrhythmias. The aim of this study was to evaluate psychotherapeutic drugs associated with life-threatening ventricular arrhythmias using the Japanese Adverse Drug Event Report (JADER) database. METHODS: From the JADER database (April 2004 to September 2022), cases of TdP, VT, VF, and QT prolongation in patients taking psychotherapeutic drugs as 'suspected drugs' were extracted...
December 2023: Journal of Arrhythmia
https://read.qxmd.com/read/38044125/a-case-of-pulmonary-edema-due-to-guanfacine-intoxication-with-measurement-of-serum-guanfacine-concentrations
#26
JOURNAL ARTICLE
Ryo Ayata, Motoki Fujita, Kayoko Harada, Yusuke Esaki, Yasutaka Koga, Yukari Hisamoto, Maki Asami-Noyama, Saki Takeda, Kazuki Harada, Ryosuke Tsuruta
Guanfacine hydrochloride extended-release (GXR) is used to treat attention deficit hyperactivity disorder. It is a selective α2A-adrenorecepor agonist that was reported to cause QT prolongation and hypotension in the event of overdosing. We report the case of a 17-year-old man who took 226 tablets of GXR 3 mg for attempted suicide. He was found complaining of dyspnea, and emergency medical services were called. When the patient was transferred to our hospital, his Glasgow coma scale was 12 (E4V3M5). He was agitated and hypoxemic...
2023: Journal of Toxicological Sciences
https://read.qxmd.com/read/38027301/case-report-guanfacine-and-methylphenidate-improved-chronic-lower-back-pain-in-autosomal-dominant-polycystic-kidney-disease-with-comorbid-attention-deficit-hyperactivity-disorder-and-autism-spectrum-disorder
#27
Satoshi Kasahara, Shoichiro Kanda, Miwako Takahashi, Mao Fujioka, Taito Morita, Ko Matsudaira, Naoko Sato, Motoshi Hattori, Toshimitsu Momose, Shin-Ichi Niwa, Kanji Uchida
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disease characterized by the bilateral development of multiple cysts in the kidneys. Pain management is a clinically important issue, especially because approximately 60% of patients with ADPKD experience chronic pain related to hemorrhage from renal cysts, which significantly reduces their daily life. The cystic fibrosis transmembrane conductance regulator, the molecule responsible for cyst formation in ADPKD, is also the cause of cystic fibrosis...
2023: Frontiers in Pediatrics
https://read.qxmd.com/read/38008401/retracing-our-steps-a-review-on-autism-research-in-children-its-limitation-and-impending-pharmacological-interventions
#28
REVIEW
Salam Salloum-Asfar, Nasser Zawia, Sara A Abdulla
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by three core impairments: impaired communication, impaired reciprocal social interaction, and restricted, repetitive, and stereotypical behavior patterns. Spectrum refers to the heterogeneity of presentation, severity of symptoms, and medical comorbidities associated with ASD. Among the most common underlying medical conditions are attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, epilepsy, digestive disorders, metabolic disorders, and immune disorders...
November 24, 2023: Pharmacology & Therapeutics
https://read.qxmd.com/read/38004497/discovery-of-guanfacine-as-a-novel-taar1-agonist-a-combination-strategy-through-molecular-modeling-studies-and-biological-assays
#29
JOURNAL ARTICLE
Elena Cichero, Valeria Francesconi, Beatrice Casini, Monica Casale, Evgeny Kanov, Andrey S Gerasimov, Ilya Sukhanov, Artem Savchenko, Stefano Espinoza, Raul R Gainetdinov, Michele Tonelli
Trace amine-associated receptor 1 (TAAR1) is an attractive target for the design of innovative drugs to be applied in diverse pharmacological settings. Due to a non-negligible structural similarity with endogenous ligands, most of the agonists developed so far resulted in being affected by a low selectivity for TAAR1 with respect to other monoaminergic G protein-coupled receptors, like the adrenoreceptors. This study utilized comparative molecular docking studies and quantitative-structure activity relationship (QSAR) analyses to unveil key structural differences between TAAR1 and alpha2-adrenoreceptor (α2 -ADR), with the aim to design novel TAAR1 agonists characterized by a higher selectivity profile and reduced off-target effects...
November 20, 2023: Pharmaceuticals
https://read.qxmd.com/read/38001266/noradrenergic-regulation-of-cue-guided-decision-making-and-impulsivity-is-doubly-dissociable-across-frontal-brain-regions
#30
JOURNAL ARTICLE
Chloe S Chernoff, Tristan J Hynes, Jackson D Schumacher, Shrishti Ramaiah, Dimitrios K Avramidis, Leili Mortazavi, Stan B Floresco, Catharine A Winstanley
RATIONALE: Win-paired stimuli can promote risk taking in experimental gambling paradigms in both rats and humans. We previously demonstrated that atomoxetine, a noradrenaline reuptake inhibitor, and guanfacine, a selective α2A adrenergic receptor agonist, reduced risk taking on the cued rat gambling task (crGT), a rodent assay of risky choice in which wins are accompanied by salient cues. Both compounds also decreased impulsive premature responding. OBJECTIVE: The key neural loci mediating these effects were unknown...
November 25, 2023: Psychopharmacology
https://read.qxmd.com/read/37961384/noradrenergic-alpha-2a-receptor-stimulation-enhances-prediction-error-signaling-in-anterior-cingulate-cortex-and-striatum
#31
Seyed A Hassani, Thilo Womelsdorf
The noradrenergic system is implicated to support behavioral flexibility by increasing exploration during periods of uncertainty and by enhancing working memory for goal-relevant stimuli. Possible sources mediating these pro-cognitive effects are α2A adrenoceptors (α2AR) in prefrontal cortex or the anterior cingulate cortex facilitating fronto-striatal learning processes. We tested this hypothesis by selectively stimulating α2ARs using Guanfacine during feature-based attentional set shifting in nonhuman primates...
October 25, 2023: bioRxiv
https://read.qxmd.com/read/37921065/an-adolescent-boy-with-kleptomania-and-attention-deficit-hyperactivity-disorder-treated-with-methylphenidate-and-guanfacine-a-case-report
#32
Kensuke Miyazaki, Michiko Uchiyama
We present the case of a patient, a boy of 16 years of age at initial presentation, with kleptomania, an impulse disorder characterized by an impulse to steal unneeded items, and attention-deficit hyperactivity disorder (ADHD). The patient's parents reported that he would frequently impulsively steal items and money that he did not need. Cognitive and physical assessments revealed no abnormalities, and the patient had no history of substance abuse. The patient was diagnosed with kleptomania and ADHD...
November 3, 2023: Neuropsychopharmacology Reports
https://read.qxmd.com/read/37890022/efficacy-of-pharmacological-and-interventional-treatment-for-resistant-hypertension-a-network-meta-analysis
#33
JOURNAL ARTICLE
Zhejia Tian, Clara Vollmer Barbosa, Hannah Lang, Johann Bauersachs, Anette Melk, Bernhard M W Schmidt
AIMS: Resistant hypertension is associated with a high risk of cardiovascular disease, chronic kidney disease, and mortality. Yet, its management is challenging. This study aims to establish the comparative effectiveness of pharmacologic and interventional treatments by conducting a network meta-analysis. METHODS AND RESULTS: MEDLINE, Cochrane Register of Controlled Trials, and Web of Science Core Collection were systematically searched in March 2022. Randomized controlled trials comparing treatment options for management of resistant hypertension were included...
February 27, 2024: Cardiovascular Research
https://read.qxmd.com/read/37721421/regulation-of-nociception-threshold-by-norepinephrine-through-adrenergic-%C3%AE-2-receptor-in-rat-models-of-parkinson-s-disease
#34
JOURNAL ARTICLE
Qing Gao, Yingying Zhang, Xiaoying Wang, Rui Wang, Limei Zhang
BACKGROUND: The mechanism of pain symptoms in Parkinson's disease (PD) is unclear. Norepinephrine (NE) regulates neuropathic pain through ascending and descending pathways. However, the loss of NE neurons in the brain of patients with PD is obvious, it is speculated that NE is involved in the occurrence of PD pain symptoms. AIMS: To investigate the effect of NE on the activation of brain cells through adrenergic α2 receptor, so as to regulate the nociception threshold in a 6-OHDA-induced animal model of PD...
September 18, 2023: CNS Neuroscience & Therapeutics
https://read.qxmd.com/read/37714122/-autism-pharmacological-treatment
#35
REVIEW
Víctor Ruggieri
Autism is a neurodevelopmental disorder characterized by deficits in social cognition and communication, restricted interests, and stereotyped behaviors. Frequently associated with sensory dysfunction, other neurodevelopmental disorders, neuropsychiatric disorders, epilepsy and/or sleep disorders. This condition will accompany people throughout their lives, which will generate various support and treatment needs. Although there are no drugs that modify the core symptoms of autism, various drugs have shown their usefulness in associated conditions...
September 2023: Medicina
https://read.qxmd.com/read/37714121/-attention-deficit-hyperactivity-pharmacotherapy-through-life
#36
REVIEW
Myriam Velarde, Angel Anicama, Aland Cárdenas
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder of biological origin with a 70 to 80% genetic basis, which affects 5% of children and adolescents and 2.5% of adults, whose main symptoms are inattention, hyperactivity, and impulsivity. For many years it was thought that it only affected children; currently in the DSM 5 it is accepted that it can be diagnosed in adolescents and adults. Treatment must be individualized, the main objectives are to improve the core symptoms of people with ADHD, and their quality of life...
September 2023: Medicina
https://read.qxmd.com/read/37713724/growing-off-label-neuro-cognitive-uses-for-guanfacine-an-informal-review-of-publications-from-2022-with-discussion-about-two-clinical-trials-scheduled-to-conclude-in-2023-2024
#37
JOURNAL ARTICLE
Brittany Woolley
No abstract text is available yet for this article.
September 15, 2023: Issues in Mental Health Nursing
https://read.qxmd.com/read/37592081/therapeutics-for-substance-using-women-the-need-to-elucidate-sex-specific-targets-for-better-tailored-treatments
#38
JOURNAL ARTICLE
Helen C Fox, Verica Milivojevic, Rajita Sinha
In the last decade, alcohol consumption in the US has risen by 84% in women compared with 35% in men. Furthermore, research has shown that sex- and gender-related differences may disadvantage women in terms of developing a range of psychological, cognitive, and medical problems considerably earlier in their drinking history than men, and despite consuming a similar quantity of substances. While this "telescoping" process has been acknowledged in the literature, a concomitant understanding of the underlying biobehavioral mechanisms, and an increase in the development of specific treatments tailored to women, has not occurred...
August 18, 2023: Handbook of Experimental Pharmacology
https://read.qxmd.com/read/37428218/noradrenergic-modulation-of-play-in-sprague-dawley-and-f344-rats
#39
JOURNAL ARTICLE
Stephen M Siviy, Michelle A Martin, Celeste M Campbell
RATIONALE: For many mammals, engaging in social play behavior as a juvenile is important for cognitive, social, and emotional health as an adult. A playful phenotype reflects a dynamic interplay between genetic framework and experiences that operate on hard-wired brain systems so the relative lack of play in an otherwise playful species may be useful for identifying neural substrates that modulate play behavior. The inbred F344 rat has been identified as a strain that is consistently less playful than other strains commonly used in behavioral research...
July 10, 2023: Psychopharmacology
https://read.qxmd.com/read/37396408/the-role-of-sex-hormones-in-targeting-stress-induced-tobacco-craving-stress-reactivity-and-smoking-with-guanfacine-among-women-who-smoke
#40
JOURNAL ARTICLE
MacKenzie R Peltier, Sherry A McKee
Women who smoke are particularly vulnerable to tobacco craving, smoking behaviors, and relapse in the context of stress when compared to men who smoke. One factor in this sex difference may be sex hormones, including estradiol and progesterone; however, smoking cessation medication trials often do not explore the impact of sex hormones on drug effects. This secondary analysis of a double-blind, placebo-controlled study explored the impact of levels of actual estradiol and progesterone on guanfacine, a noradrenergic α2a agonist, which attenuates stress-induced smoking behaviors in women...
September 2023: Addict Neurosci
keyword
keyword
7575
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.